piramal desflurane desflurane 1 ml/ml inhalation bottle
piramal critical care pty ltd - desflurane, quantity: 1 ml/ml - inhalation - excipient ingredients: - piramal desflurane is indicated as an inhalation agent for maintenance of anaesthesia. desflurane is not recommended for mask induction of anaesthesia because of a high incidence of moderate to severe upper airway adverse events.
desflurane sandoz desflurane 1 ml/ml inhalation bottle
sandoz pty ltd - desflurane, quantity: 1 ml/ml - inhalation - excipient ingredients: - desflurane sandoz is indicated as an inhalation agent for maintenance of anaesthesia. desflurane sandoz is not recommended for mask induction of anaesthesia because of a high incidence of moderate to severe upper airway adverse events.
corteva agriscience rizacon s igr grain protector
corteva agriscience australia pty ltd - (s)-methoprene; liquid hydrocarbon - emulsifiable concentrate - (s)-methoprene terpene active 300.0 g/l; liquid hydrocarbon solvent other 401.0 g/l - insecticide - stored cereal grain | malting barley | sorghum - grain weevil | lesser grain borer | lesser grain borer - op resistant | rust-red flour beetle | rust-red flour beetle - op resistant | sawtoothed grain beetle | sawtoothed grain beetle - op resistant | stored grain insect pests - inclusions | beetles organophosphate resist | grain borer | granary weevil | indian meal moth | lesser grain borer | rice weevil | rust-red flour beetle | sawtoothed grain beetle | sitophilus granarius | sitophilus oryzae | sitophilus zeamais | tropical warehouse moth
ac axistrobin 250 sc fungicide
axichem pty ltd - azoxystrobin - suspension concentrate - azoxystrobin pyrimidine active 250.0 g/l - fungicide
blooms the chemist escitalopram escitalopram (as oxalate) 20 mg tablet blister
arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.47 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 400; magnesium stearate; purified talc; hypromellose; croscarmellose sodium; titanium dioxide; colloidal anhydrous silica - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder
blooms the chemist escitalopram escitalopram (as oxalate) 10 mg tablet blister
arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.74 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; croscarmellose sodium; macrogol 400; hypromellose; titanium dioxide; microcrystalline cellulose; magnesium stearate - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder
septanest 1:200,000 articaine hcl 4% with adrenaline 1:200,000, solution for injection 2.2 ml cartridge
specialites septodont pty ltd - articaine hydrochloride, quantity: 88 mg; adrenaline (epinephrine) acid tartrate, quantity: 0.02 mg (equivalent: adrenaline (epinephrine), qty 0.011 mg) - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; sodium hydroxide; water for injections - ? septanest 1:200,000 is indicated for local anaesthesia for simple dental procedures in adults, adolescents and children 4 years of age and older. ? septanest 1:200,000 is indicated only for dental procedures
buprenorphine sandoz buprenorphine 5 micrograms/hour transdermal drug delivery system sachet
sandoz pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.
buprenorphine sandoz buprenorphine 20 micrograms/hour transdermal drug delivery system sachet
sandoz pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.
buprenorphine sandoz buprenorphine 15 micrograms/hour transdermal drug delivery system sachet
sandoz pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.